Gefitinib (Iressa) — targeted treatment for EGFR-related lung cancer

What gefitinib is in simple patient language

Iressa — brand name. Gefitinib — the drug name in medical records. A cancer tablet. A targeted drug. Not regular chemotherapy. Not immunotherapy. And not a pill to start just because the diagnosis says lung cancer.

Why it comes up: some lung tumors run on an EGFR signal. The report has to show that signal problem. Without the EGFR result, the choice is guesswork.

The tablet is small. The decision is not. The doctor looks at the exact EGFR change, scans, earlier treatment, breathing, skin, bowel history, liver numbers, other medicines, and the patient’s strength. One word in a diagnosis line is not enough.

How gefitinib works

Some lung cancer cells use EGFR like a stuck switch. The cell keeps receiving a growth order. Gefitinib tries to press on that switch from inside the cell.

When the tumor really depends on EGFR, the disease may slow down. Spots may shrink. Sometimes the useful result is less dramatic: the cancer stops moving so fast.

The tablet can still be rough. Skin, bowel, liver tests, cough, and breathing all matter here. A patient can take Iressa at home, but the treatment still belongs to oncology.

Which diseases gefitinib may be used for

Gefitinib is not a general lung-cancer pill. It is discussed only when the tumor story fits an EGFR-directed plan.

• lung cancer of the non-small-cell group with an EGFR mutation that fits this kind of treatment;
• lung adenocarcinoma, when the molecular report supports an EGFR tablet;
• advanced or metastatic disease where the whole body needs treatment, not only a local step;
• a later treatment decision after earlier therapy, if the doctor is comparing EGFR options;
• a second opinion when Iressa was offered and the family wants to understand why.

Same cancer name does not mean the same plan. One patient may need Iressa. Another may need a different EGFR drug, chemotherapy, a trial, or treatment for symptoms first.

When gefitinib can be especially relevant

The conversation usually starts after the EGFR test, not before it. If the test fits, the doctor then asks a practical question: is this tablet the right EGFR choice for today?

• the EGFR mutation is confirmed, not only suspected;
• the disease needs systemic treatment;
• a tablet plan is being compared with other EGFR medicines;
• earlier treatment history has to be sorted before the next step;
• rash, diarrhea, cough, or liver tests already make the safety plan important.

The question is not whether the drug sounds strong. The question is what job it has now, and whether a better-timed or safer option exists.

What needs to be checked before treatment

Before Iressa, the doctor needs more than a prescription line. The starting point has to be clear.

• the type of lung cancer seen on pathology;
• the EGFR result, with the exact mutation written out;
• fresh CT, PET-CT, MRI, or other scans used for the decision;
• brain MRI information, if symptoms or the disease pattern make it relevant;
• what treatment was already given and why it stopped;
• blood work, liver values, kidney values;
• cough, shortness of breath, chest discomfort, fever, or other lung symptoms;
• skin and bowel history;
• the full home medicine list, including pills taken only sometimes.

A new breathing complaint can change the order of steps. So can unclear EGFR testing, active diarrhea, bad liver numbers, or a drug conflict. It is better to catch that before the first tablet.

How treatment with gefitinib goes

Gefitinib is taken by mouth on the schedule set by the oncologist. It looks simpler than an infusion. It is not simpler medically.

At the start, the team usually watches the places where this drug causes trouble: skin, gut, liver, lungs, appetite, weight, and general strength. Scans are planned later to see what the cancer is doing.

During treatment, doctors usually follow:

• skin rash, dryness, itching, cracks, or soreness;
• diarrhea, nausea, appetite, weight, and fluid intake;
• cough, breathing, chest pain, or fever;
• liver tests and blood chemistry;
• eye irritation, pain, or vision change;
• planned imaging compared with earlier scans;
• whether the tablet still makes sense and is safe enough to continue.

A rash or diarrhea is not always the end of treatment. It is also not something to hide. The doctor may treat the symptom, hold the drug, or change the plan. Guessing at home is the unsafe part.

Possible side effects

People do not all react the same way. One person mainly has skin trouble. Another has bowel trouble. Another has liver-test changes without much feeling at first.

• rash, dry skin, itching, soreness, or cracks;
• diarrhea, nausea, poor appetite, weight loss;
• mouth soreness or small ulcers;
• weakness or a tired feeling that does not fit the usual day;
• liver numbers going up in blood tests;
• new cough or heavier breathing;
• rare lung inflammation that needs a fast check;
• eye pain, redness, irritation, or blurred vision;
• a general drop in condition without a clear reason.

Small changes can still matter. Tell the clinic early, while the problem is still small. It is much easier to adjust a plan before the patient is dry, weak, or short of breath.

When the treating team needs to know fast

Call the doctor the same day if any of these start:

• new shortness of breath, or breathing that is getting worse;
• strong cough, chest pain, fever, or chills;
• diarrhea that repeats, or trouble keeping fluids down;
• yellow skin or yellow eyes, very dark urine, or strong pain on the right side of the belly;
• rash that spreads fast, hurts, blisters, or comes with fever;
• eye pain, strong redness, or sudden change in vision;
• fainting, very strong weakness, or a quick drop in general condition.

The patient does not need to prove that Iressa caused it. The doctor can decide that. The patient’s job is to report the change before the situation becomes harder to fix.

Why gefitinib is not right for everyone

Gefitinib may fit one EGFR-positive case and still be wrong for another. The drug is not chosen from the cancer name alone.

• the EGFR mutation is not found, or the result is doubtful;
• another EGFR drug fits the situation better;
• there are breathing symptoms that need an explanation first;
• liver values are already a problem;
• past EGFR treatment caused serious trouble;
• other medicines make the plan less safe;
• the patient is too weak for this step now.

Choosing another route does not mean Iressa is a bad drug. It may simply be the wrong tool for this moment.

Can gefitinib be combined with other treatments

Sometimes gefitinib is part of a longer cancer plan. That does not mean it should be added to everything.

• after surgery or radiation, if the full plan supports that step;
• after earlier systemic treatment, when the doctor is changing direction;
• with support for rash, diarrhea, appetite, and general condition;
• while separate spots in brain, bone, lung, or liver are followed on scans;
• in comparison with another EGFR medicine or a clinical trial.

More treatment is not automatically better treatment. Each step needs a reason. Each added drug adds its own risk.

What no quick response can mean

The first days usually do not give the full answer. A patient may feel the same. Or feel worse because of side effects. The scans and symptoms have to be read together.

Sometimes the good sign is a smaller tumor. Sometimes it is quieter disease. Sometimes the main issue is not the cancer yet, but whether the body can tolerate the tablet.

Do not judge the plan from one day. Also do not ignore new symptoms. Cough, breathing, rash, diarrhea, eye pain, or liver-test changes can change the plan before the next scan.

Oncology consultation in Israel about gefitinib

At Tel Aviv Medical Clinic, a patient can review whether gefitinib has a clear place in the current EGFR-positive lung-cancer plan.

This is useful when Iressa was offered, but the reason is not clear, when another EGFR drug is also being discussed, or when rash, diarrhea, cough, liver tests, or eye symptoms are already part of the story.

For the consultation, bring the biopsy report, EGFR test, recent scans, brain MRI if done, previous treatment list, blood tests, liver values, current symptoms, and the home medicine list.

We do not prescribe treatment remotely and do not replace the treating physician. The aim is to help the patient understand the logic and prepare better questions.

Frequently asked questions — answered by Dr. Stefanska

1. Is Iressa chemotherapy?

No. Iressa belongs to the EGFR-targeted group. A tablet, not infusion chemo. Different job.

The word “tablet” can mislead people. Skin, loose stool, liver numbers, cough, breathing, and eyes still need watching. Home use does not make it casual.

2. Why does the EGFR test matter so much?

Iressa needs something to aim at. “Lung cancer” is not enough. The tumor report has to show an EGFR change that fits this kind of drug.

The exact mutation matters. The sample matters. The date of the test matters. If that part is old or unclear, the next step can be built on sand.

3. How is gefitinib different from osimertinib?

Same EGFR road, different medicines. One is not chosen just because the name sounds newer, older, stronger, or more familiar.

First line up the mutation, brain MRI, previous tablets, why they stopped, side effects, and access to the drug. Only then does the comparison make sense.

4. Should the drug be stopped if rash appears?

Not by guessing. A few spots and a painful spreading rash are not the same story.

Take a photo. Tell the clinic when it started, where it is, whether it hurts, whether there is fever, wet skin, eye pain, or blisters. The team can decide about creams, a pause, dose discussion, or a visit.

5. Which symptoms should not stay at home?

New breathing trouble. Chest pain. Fever. Heavy diarrhea. Yellow eyes. Painful rash. Eye pain. Sudden strong weakness. These are not “wait and see” symptoms.

With Iressa, cough and breathing can come from different places: infection, the cancer itself, or a lung reaction to treatment. This cannot be sorted safely from the sofa.

6. Can a patient take a short break from Iressa?

Only if the doctor says so. Stopping an EGFR tablet for a few days is not a harmless private decision.

The reason for the pause changes everything: diarrhea, rash, liver tests, breathing, another medicine. Restarting also needs instructions, not guesswork.

7. What should be prepared for a second opinion?

Bring the biopsy report, EGFR result, recent CT or PET-CT, brain MRI if done, treatment dates, side effects, and fresh blood and liver tests.

Also bring one short timeline: diagnosis, EGFR result, treatment given, what helped, what failed, what stopped the plan, and what the main question is now.

Important information

This page is general medical information. It is not a prescription, and it does not replace the treating doctor.

Gefitinib can be discussed only after the diagnosis, EGFR result, scans, earlier treatment, blood tests, liver values, symptoms, other medicines, and general condition are reviewed.

Do not start, stop, or change the dose on your own. New breathing problems, heavy diarrhea, yellow skin or eyes, painful rash, fever, eye pain, or a fast drop in condition should be reported quickly.

Contacts

For a consultation about Gefitinib:

📞 +972-73-374-6844
📧 [email protected]
💬 WhatsApp: +972-52-337-3108